Clinical Trial Info

Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (I-TECH)

Authored by

This is a multicenter, Phase 3 open-label, randomized controlled clinical trial involving COVID-19 designated hospitals in Malaysia.

490 patients are randomized at a ratio of 1:1 to groups receiving ivermectin for 5 days plus standard-of-care versus standard-of-care only.

Patients will be assigned to stratified randomized treatments based on a central, computer-generated randomization scheme coordinated by an independent third party. Based on national guidelines, all high-risk COVID-19 patients will be admitted to hospitals, and allowed discharge once criteria are met.

On February 18, 2022, the Jama Network published an original investigation into this trial data. Their findings are below.


Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group).


In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19.